Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a phone app replace In-Person heart rehab? new study says maybe.

NCT ID NCT05238103

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a virtual cardiac rehabilitation program using a smartphone app, a fitness wristband, and a blood pressure monitor for people who recently had a heart attack, heart surgery, or a stent. The goal was to see if this home-based program could improve walking ability, cholesterol, and overall heart health compared to traditional in-person rehab. The trial enrolled 259 adults and followed them for 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Corrie Hybrid Cardiac Rehabilitation Program (smartphone app, wristband, blood pressure monitor, exercise bands, health coaching)
What this could lead to
If successful, this could show that a virtual cardiac rehab program is as good as or better than in-person rehab for improving heart health and quality of life.
What could go wrong
This is a completed trial, but it is relatively small (259 participants) and only followed patients for 12 weeks. Results may not apply to all heart patients or show long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

259 people

The number who actually took part.

Started

Apr 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years or older * Individuals admitted to the hospital for the following conditions or interventions during the index admission: Acute myocardial infarction (STEMI or NSTEMI type 1), Coronary artery bypass grafting (CABG), and Coronary artery angioplasty/stenting (PCI), Heart valve surgery, catheter-based aortic valve replacement (TAVR). Exclusion Criteria * Non-English speaking * Symptomatic severe aortic stenosis or other severe valvular disease * Physical disability that would preclude safe and adequate exercise performance * Hypertrophic obstructive cardiomyopathy with peak resting left ventricular outflow gradient of \>25 mmHg * Known aortic dissection * Severe resting arterial hypertension (Systolic blood pressure \>200 mmHg or diastolic BP \>110mmHg) at baseline assessment * Mental impairment leading to inability to cooperate with study procedures * Untreated high degree atrioventricular block * Atrial fibrillation with uncontrolled ventricular rate (Heart rate \>110 at rest) at baseline assessment * History of cardiac arrest or sudden death * Myocardial infarction or cardiac surgery complications with cardiogenic shock and/or congestive heart failure and/or signs/symptoms of post-procedure ischemia * Left ventricular ejection fraction \<40% * History of Clinically significant depression * Visual or hearing impairment which precludes the use of the intervention * Presence of cardiac defibrillator * Incomplete revascularization procedure * History of one or more episodes of falls in the last year * Pregnancy * If patients are deemed clinically unstable and unable to participate at the time of initial screening, the research team member may return at a later date to determine whether this status has changed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bypass graft occlusion are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.